Ruxolitinib alleviates DSS-induced acute ulcerative colitis by inhibiting STAT1 phosphorylation and reducing MDSC infiltration.

Although the average spleen weight in the Ruxolitinib-treated group was lower compared to the model group ( Figure 2B ), this difference did not reach statistical significance.

also in 111,027 other papers